Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Author(s)
Patel, A. P.; Tirosh, I.; Trombetta, J. J.; Gillespie, S. M.; Wakimoto, H.; Cahill, D. P.; Nahed, B. V.; Curry, W. T.; Martuza, R. L.; Louis, D. N.; Rozenblatt-Rosen, O.; Suva, M. L.; Bernstein, Bradley E.; Regev, Aviv; Shalek, Alex K.; ... Show more Show less
DownloadRegev_Single cell rna.pdf (2.152Mb)
OPEN_ACCESS_POLICY
Open Access Policy
Creative Commons Attribution-Noncommercial-Share Alike
Terms of use
Metadata
Show full item recordAbstract
Human cancers are complex ecosystems composed of cells with distinct phenotypes, genotypes, and epigenetic states, but current models do not adequately reflect tumor composition in patients. We used single-cell RNA sequencing (RNA-seq) to profile 430 cells from five primary glioblastomas, which we found to be inherently variable in their expression of diverse transcriptional programs related to oncogenic signaling, proliferation, complement/immune response, and hypoxia. We also observed a continuum of stemness-related expression states that enabled us to identify putative regulators of stemness in vivo. Finally, we show that established glioblastoma subtype classifiers are variably expressed across individual cells within a tumor and demonstrate the potential prognostic implications of such intratumoral heterogeneity. Thus, we reveal previously unappreciated heterogeneity in diverse regulatory programs central to glioblastoma biology, prognosis, and therapy.
Date issued
2014-06Department
Massachusetts Institute of Technology. Department of Biology; Massachusetts Institute of Technology. Department of ChemistryJournal
Science
Publisher
American Association for the Advancement of Science (AAAS)
Citation
Patel, A. P., I. Tirosh, J. J. Trombetta, A. K. Shalek, S. M. Gillespie, H. Wakimoto, D. P. Cahill, et al. “Single-Cell RNA-Seq Highlights Intratumoral Heterogeneity in Primary Glioblastoma.” Science 344, no. 6190 (June 12, 2014): 1396–1401.
Version: Author's final manuscript
ISSN
0036-8075
1095-9203